{"protocolSection":{"identificationModule":{"nctId":"NCT01603615","orgStudyIdInfo":{"id":"191622-105"},"secondaryIdInfos":[{"id":"2012-000043-27","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Allergan","class":"INDUSTRY"},"briefTitle":"BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity","officialTitle":"BOTOX® Treatment in Pediatric Upper Limb Spasticity: Open-label Study"},"statusModule":{"statusVerifiedDate":"2019-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-10-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-09-03","type":"ACTUAL"},"completionDateStruct":{"date":"2018-09-03","type":"ACTUAL"},"studyFirstSubmitDate":"2012-05-21","studyFirstSubmitQcDate":"2012-05-21","studyFirstPostDateStruct":{"date":"2012-05-22","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-07-29","resultsFirstSubmitQcDate":"2019-07-29","resultsFirstPostDateStruct":{"date":"2019-08-21","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-07-29","lastUpdatePostDateStruct":{"date":"2019-08-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Allergan","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity."},"conditionsModule":{"conditions":["Pediatrics","Muscle Spasticity","Cerebral Palsy","Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":220,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"BOTOX®","type":"EXPERIMENTAL","description":"Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study.","interventionNames":["Biological: Botulinum Toxin Type A"]}],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum Toxin Type A","description":"Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.","armGroupLabels":["BOTOX®"],"otherNames":["BOTOX® OnabotulinumtoxinA"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With at Least One Treatment- Emergent Adverse Event (TEAE)","description":"An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A TEAE was an AE that occurred after receiving the first dose of investigational product or an AE present prior to first dose but increased in severity during the Treatment Period. Safety population included all treated participants.","timeFrame":"From first dose of study drug up to 12 weeks post last dose (Up to 60 weeks)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Minimum weight of 10 Kilograms (kg) / 22 Pounds (lb)\n* Upper limb spasticity due to cerebral palsy or stroke\n\nExclusion Criteria:\n\n* Muscular dystrophy, myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or mitochondrial disease\n* Uncontrolled epilepsy\n* Botulinum Toxin therapy of any serotype for any condition within the last 3 months\n* History of surgical intervention of the upper limb within 1 year, or planned surgery of any limb during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Emily McCusker","affiliation":"Allergan","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"ABS Health, LLC","city":"Pasadena","state":"California","zip":"91106","country":"United States","geoPoint":{"lat":34.14778,"lon":-118.14452}},{"facility":"Harrison Clinical Management","city":"Pomona","state":"California","zip":"91767","country":"United States","geoPoint":{"lat":34.05529,"lon":-117.75228}},{"facility":"Rady Children's Hospital San Diego","city":"San Diego","state":"California","zip":"92123","country":"United States","geoPoint":{"lat":32.71533,"lon":-117.15726}},{"facility":"Children's Hospital Colorado Dept. of PM&R","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Associated Neurologists of Southern Connecticut, P.C.","city":"Fairfield","state":"Connecticut","zip":"06824","country":"United States","geoPoint":{"lat":41.14121,"lon":-73.26373}},{"facility":"New England Center for Clinical Research","city":"Stamford","state":"Connecticut","zip":"06905","country":"United States","geoPoint":{"lat":41.05343,"lon":-73.53873}},{"facility":"NW FL Clinical Research Group, LLC","city":"Gulf Breeze","state":"Florida","zip":"32561","country":"United States","geoPoint":{"lat":30.35714,"lon":-87.16386}},{"facility":"Axcess Medical Research, LLC","city":"Loxahatchee Groves","state":"Florida","zip":"33470","country":"United States","geoPoint":{"lat":26.68368,"lon":-80.27977}},{"facility":"Pediatric Neurology, PA","city":"Orlando","state":"Florida","zip":"32891","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Children's Healthcare of Atlanta Children's Rehabilitation Associates","city":"Atlanta","state":"Georgia","zip":"30342","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Gillette Children's Specialty Healthcare","city":"Saint Paul","state":"Minnesota","zip":"55101","country":"United States","geoPoint":{"lat":44.94441,"lon":-93.09327}},{"facility":"The Children's Mercy Hospital & Clinics","city":"Kansas City","state":"Missouri","zip":"64108","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Washington University School of Medicine","city":"Saint Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Clinical Research Center of New Jersey","city":"Voorhees","state":"New Jersey","zip":"08043","country":"United States","geoPoint":{"lat":40.48122,"lon":-74.48321}},{"facility":"NYU Hospital for Joint Diseases","city":"New York","state":"New York","zip":"10003","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Columbia University Pediatric Physical Medicine & Rehabilitation, Dept. of Rehabilitation & Regenerative Medicine Harkness","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"OnSite Clinical Solutions, LLC","city":"Charlotte","state":"North Carolina","zip":"28203","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"PMG Research of Charlotte, LLC","city":"Charlotte","state":"North Carolina","zip":"28203","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Vanderbilt University Medical Center","city":"Nashville","state":"Tennessee","zip":"37232","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"University of Texas Southwestern Medical Center","city":"Dallas","state":"Texas","zip":"75235","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Baylor College of Medicine Texas Children's Hospital","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Road Runner Research","city":"San Antonio","state":"Texas","zip":"78249","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Seattle Children's Hospital","city":"Seattle","state":"Washington","zip":"98105","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Marshfield Clinic","city":"Marshfield","state":"Wisconsin","zip":"54449","country":"United States","geoPoint":{"lat":44.66885,"lon":-90.1718}},{"facility":"Holland Bloorview Kids Rehab","city":"Toronto","state":"Ontario","zip":"M4G 1R8","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"Debrecen University Clinical Center, Orthopedic Clinic","city":"Debrecen","zip":"4032","country":"Hungary","geoPoint":{"lat":47.53333,"lon":21.63333}},{"facility":"Daegu Fatima Hospital","city":"Daegu","zip":"41199","country":"Korea, Republic of","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"National Health Insurance Service Ilsan Hospital","city":"Gyeonggi-do","zip":"10444","country":"Korea, Republic of","geoPoint":{"lat":37.58944,"lon":126.76917}},{"facility":"Seoul National University Hospital","city":"Seoul","zip":"03080","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Severance Hospital, Yonsei University Health System","city":"Seoul","zip":"03722","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center","city":"Seoul","zip":"05505","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center","city":"Seoul","zip":"06351","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"De La Salle Health Sciences Institute","city":"Cavite","zip":"4114","country":"Philippines","geoPoint":{"lat":15.67785,"lon":120.76978}},{"facility":"Philippine Children's Medical Center","city":"Quezon City","zip":"1104","country":"Philippines","geoPoint":{"lat":14.6488,"lon":121.0509}},{"facility":"Uni Centrum Kliniczne","city":"Gdansk","zip":"80-219","country":"Poland","geoPoint":{"lat":54.35205,"lon":18.64637}},{"facility":"Specjal. Gabinet Neurologiczny","city":"Krakow","zip":"30-539","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Centrum Medyczne \"POMOC\"","city":"Lodz","zip":"93-271","country":"Poland","geoPoint":{"lat":51.75,"lon":19.46667}},{"facility":"INTERMED, Lublin","city":"Lublin","zip":"20-058","country":"Poland","geoPoint":{"lat":51.25,"lon":22.56667}},{"facility":"CRH ŻAGIEL MED, Lublin","city":"Lublin","zip":"20-601","country":"Poland","geoPoint":{"lat":51.25,"lon":22.56667}},{"facility":"Centrum Profilatyki I Terapii","city":"Warsaw","zip":"02-383","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"NZOZ Mazowieckie Centrum","city":"Warsaw","zip":"05-462","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Childrens Republic Hospital","city":"Kazan","zip":"420138","country":"Russian Federation","geoPoint":{"lat":55.78874,"lon":49.12214}},{"facility":"Smolensk Regional Hospital- Regional Budget State Healthcare institution","city":"Smolensk","zip":"214018","country":"Russian Federation","geoPoint":{"lat":54.7818,"lon":32.0401}},{"facility":"Tyumen Regional Hospital #2 - State Budget Healthcare Institution of Tyumen region","city":"Tyumen","zip":"625039","country":"Russian Federation","geoPoint":{"lat":57.15222,"lon":65.52722}},{"facility":"Siriraj Hospital Dept of Rehabilitation Medicine, Faculty of Medicine","city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University","city":"Chiang Mai","zip":"50200","country":"Thailand","geoPoint":{"lat":18.79038,"lon":98.98468}},{"facility":"Srinagarind Hospital, Khon Kaen University","city":"Khon Kaen","zip":"40002","country":"Thailand","geoPoint":{"lat":16.44671,"lon":102.833}},{"facility":"Kocaeli Üniversitesi","city":"Kocaeli","zip":"41050","country":"Turkey","geoPoint":{"lat":39.62497,"lon":27.51145}}]},"referencesModule":{"seeAlsoLinks":[{"label":"More information","url":"http://www.allerganclinicaltrials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Pediatric participants with Upper Limb Spasticity who were previously treated with BOTOX® in study 191622-101 \\[NCT01603602\\] and de novo participants received up to 5 BOTOX® treatments in this study.","groups":[{"id":"FG000","title":"BOTOX®","description":"Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"220"}]},{"type":"Safety Population (Treated)","achievements":[{"groupId":"FG000","numSubjects":"213"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"186"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"34"}]}],"dropWithdraws":[{"type":"Did not Receive Treatment","reasons":[{"groupId":"FG000","numSubjects":"7"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"9"}]},{"type":"Personal Reasons","reasons":[{"groupId":"FG000","numSubjects":"17"}]},{"type":"Other Miscellaneous","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population included all treated participants.","groups":[{"id":"BG000","title":"BOTOX®","description":"Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"213"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.3","spread":"4.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"85"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"128"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"130"}]},{"title":"Black","measurements":[{"groupId":"BG000","value":"9"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"61"}]},{"title":"Hispanic","measurements":[{"groupId":"BG000","value":"10"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"3"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least One Treatment- Emergent Adverse Event (TEAE)","description":"An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A TEAE was an AE that occurred after receiving the first dose of investigational product or an AE present prior to first dose but increased in severity during the Treatment Period. Safety population included all treated participants.","populationDescription":"Safety population included all treated participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From first dose of study drug up to 12 weeks post last dose (Up to 60 weeks)","groups":[{"id":"OG000","title":"BOTOX®","description":"Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.7"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From first dose of study drug up to 12 weeks post last dose (Up to 60 weeks)","description":"Safety population included all treated participants.","eventGroups":[{"id":"EG000","title":"BOTOX®","description":"Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study.","deathsNumAffected":0,"deathsNumAtRisk":213,"seriousNumAffected":13,"seriousNumAtRisk":213,"otherNumAffected":57,"otherNumAtRisk":213}],"seriousEvents":[{"term":"Cryptorchism","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Food poisoning","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Meningitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Joint contracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Juvenile idiopathic arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":213}]},{"term":"Hemiplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Status epilepticus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":213}]}],"otherEvents":[{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":213}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":213}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":213}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."},"pointOfContact":{"title":"Therapeutic Area, Head","organization":"Allergan","email":"clinicaltrials@allergan.com","phone":"714-246-4500"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2016-08-01","uploadDate":"2019-07-29T17:34","filename":"Prot_000.pdf","size":805721},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-01-14","uploadDate":"2019-07-29T17:34","filename":"SAP_001.pdf","size":357633}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Italy"]},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000002547","term":"Cerebral Palsy"}],"ancestors":[{"id":"D000001925","term":"Brain Damage, Chronic"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M12847","name":"Paralysis","relevance":"LOW"},{"id":"M5486","name":"Cerebral Palsy","asFound":"Cerebral Palsy","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M4897","name":"Brain Injuries","relevance":"LOW"},{"id":"M4892","name":"Brain Damage, Chronic","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC26","name":"Wounds and Injuries"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Previous","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Previous","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":true}